{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:35:54Z","timestamp":1783488954280,"version":"3.55.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR055670"],"award-info":[{"award-number":["R01AR055670"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Multiple hereditary exostoses (MHE), also known as multiple osteochondromas (MO), is an autosomal dominant disorder characterized by the development of multiple cartilage-capped bone tumors (osteochondromas). The large majority of patients with MHE carry loss-of-function mutations in the EXT1 or EXT2 gene, which encodes a glycosyltransferase essential for heparan sulfate (HS) biosynthesis. Increasing evidence suggests that enhanced bone morphogenetic protein (BMP) signaling resulting from loss of HS expression plays a role in osteochondroma formation in MHE. Palovarotene (PVO) is a retinoic acid receptor \u03b3 selective agonist, which is being investigated as a potential drug for fibrodysplasia ossificans progressiva (FOP), another genetic bone disorder with features that overlap with those of MHE. Here we show that PVO inhibits osteochondroma formation in the Fsp1Cre;Ext1flox\/flox model of MHE. Four-week daily treatment with PVO starting at postnatal day (P) 14 reduced the number of osteochondromas that develop in these mice by up to 91% in a dose-dependent manner. An inhibition of long bone growth observed in animals treated from P14 was almost entirely abrogated by delaying the initiation of treatment to P21. We also found that PVO attenuates BMP signaling in Fsp1Cre;Ext1flox\/flox mice and that aberrant chondrogenic fate determination of Ext1-deficient perichondrial progenitor cells in these mice is restored by PVO. Together, the present data support further preclinical and clinical investigations of PVO as a potential therapeutic agent for MHE. \u00a9 2017 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.3341","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T13:32:40Z","timestamp":1510234360000},"page":"658-666","source":"Crossref","is-referenced-by-count":43,"title":["Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses"],"prefix":"10.1093","volume":"33","author":[{"given":"Toshihiro","family":"Inubushi","sequence":"first","affiliation":[{"name":"Human Genetics ProgramSanford Burnham Prebys Medical Discovery InstituteLa JollaCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lemire","sequence":"additional","affiliation":[{"name":"Clementia Pharmaceuticals Inc.MontrealCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitoshi","family":"Irie","sequence":"additional","affiliation":[{"name":"Human Genetics ProgramSanford Burnham Prebys Medical Discovery InstituteLa JollaCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Human Genetics ProgramSanford Burnham Prebys Medical Discovery InstituteLa JollaCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"key":"2024021014360165900_jbmr3341-bib-0001","author":"Wuyts","year":"2013"},{"issue":"(7)","key":"2024021014360165900_jbmr3341-bib-0002","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2106\/00004623-199407000-00005","article-title":"The natural history of hereditary multiple exostoses","volume":"76","author":"Schmale","year":"1994","journal-title":"J Bone Joint Surg Am"},{"issue":"(3)","key":"2024021014360165900_jbmr3341-bib-0003","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/embo-reports\/kvd045","article-title":"The EXT1\/EXT2 tumor suppressors: catalytic activities and role in heparan sulfate biosynthesis","volume":"1","author":"Senay","year":"2000","journal-title":"EMBO Rep"},{"issue":"(7139)","key":"2024021014360165900_jbmr3341-bib-0004","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/nature05817","article-title":"Heparan sulphate proteoglycans fine-tune mammalian physiology","volume":"446","author":"Bishop","year":"2007","journal-title":"Nature"},{"issue":"(25)","key":"2024021014360165900_jbmr3341-bib-0005","doi-asserted-by":"crossref","first-page":"19227","DOI":"10.1074\/jbc.M110.105338","article-title":"Conditional ablation of the heparan sulfate-synthesizing enzyme Ext1 leads to dysregulation of bone morphogenic protein signaling and severe skeletal defects","volume":"285","author":"Matsumoto","year":"2010","journal-title":"J Biol Chem"},{"issue":"(6)","key":"2024021014360165900_jbmr3341-bib-0006","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.devcel.2004.05.009","article-title":"Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification","volume":"6","author":"Koziel","year":"2004","journal-title":"Dev Cell"},{"issue":"(1)","key":"2024021014360165900_jbmr3341-bib-0007","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ydbio.2013.02.008","article-title":"Perichondrium phenotype and border function are regulated by Ext1 and heparan sulfate in developing long bones: a mechanism likely deranged in hereditary multiple exostoses","volume":"377","author":"Huegel","year":"2013","journal-title":"Dev Biol"},{"issue":"15","key":"2024021014360165900_jbmr3341-bib-0008","doi-asserted-by":"crossref","first-page":"90049","DOI":"10.1172\/jci.insight.90049","article-title":"Aberrant perichondrial BMP signaling mediates multiple osteochondromagenesis in mice","volume":"2","author":"Inubushi","year":"2017","journal-title":"JCI Insight"},{"issue":"(4)","key":"2024021014360165900_jbmr3341-bib-0009","doi-asserted-by":"crossref","first-page":"e1006742","DOI":"10.1371\/journal.pgen.1006742","article-title":"Unsuspected osteochondroma-like outgrowths in the cranial base of hereditary multiple exostoses patients and modeling and treatment with a BMP antagonist in mice","volume":"13","author":"Sinha","year":"2017","journal-title":"PLoS Genet"},{"issue":"(2)","key":"2024021014360165900_jbmr3341-bib-0010","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5435\/00124635-200503000-00004","article-title":"Manifestations of hereditary multiple exostoses","volume":"13","author":"Stieber","year":"2005","journal-title":"J Am Acad Orthop Surg"},{"issue":"(3)","key":"2024021014360165900_jbmr3341-bib-0011","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/01.bpo.0000150813.18673.ad","article-title":"Hereditary multiple exostosis and pain","volume":"25","author":"Darilek","year":"2005","journal-title":"J Pediatr Orthop"},{"issue":"7","key":"2024021014360165900_jbmr3341-bib-0012","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1302\/0301-620X.86B7.14815","article-title":"Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study","volume":"86","author":"Porter","year":"2004","journal-title":"J Bone Joint Surg Br"},{"issue":"(5)","key":"2024021014360165900_jbmr3341-bib-0013","first-page":"633","article-title":"Osteochondromas: review of the clinical, radiological and pathological features","volume":"22","author":"Kitsoulis","year":"2008","journal-title":"In Vivo"},{"issue":"(15)","key":"2024021014360165900_jbmr3341-bib-0014","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1016\/j.bmcl.2008.06.052","article-title":"Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors","volume":"18","author":"Cuny","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"2024021014360165900_jbmr3341-bib-0015","first-page":"1243","article-title":"Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema","volume":"10","author":"Hind","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"issue":"(2)","key":"2024021014360165900_jbmr3341-bib-0016","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1183\/09031936.00161911","article-title":"Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor","volume":"40","author":"Stolk","year":"2012","journal-title":"Eur Respir J"},{"issue":"(4)","key":"2024021014360165900_jbmr3341-bib-0017","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nm.2334","article-title":"Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists","volume":"17","author":"Shimono","year":"2011","journal-title":"Nat Med"},{"issue":"(3)","key":"2024021014360165900_jbmr3341-bib-0018","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bone.2008.05.013","article-title":"Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP)","volume":"43","author":"Shore","year":"2008","journal-title":"Bone"},{"issue":"(5)","key":"2024021014360165900_jbmr3341-bib-0019","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","article-title":"A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva","volume":"38","author":"Shore","year":"2006","journal-title":"Nat Genet"},{"issue":"(12)","key":"2024021014360165900_jbmr3341-bib-0020","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/nm.1888","article-title":"BMP type I receptor inhibition reduces heterotopic [corrected] ossification","volume":"14","author":"Yu","year":"2008","journal-title":"Nat Med"},{"issue":"(2)","key":"2024021014360165900_jbmr3341-bib-0021","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2106\/JBJS.G.00774","article-title":"Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva","volume":"90","author":"Deirmengian","year":"2008","journal-title":"J Bone Joint Surg Am"},{"issue":"(5647)","key":"2024021014360165900_jbmr3341-bib-0022","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1126\/science.1090497","article-title":"Mammalian brain morphogenesis and midline axon guidance require heparan sulfate","volume":"302","author":"Inatani","year":"2003","journal-title":"Science"},{"issue":"(5659)","key":"2024021014360165900_jbmr3341-bib-0023","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.1090922","article-title":"TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia","volume":"303","author":"Bhowmick","year":"2004","journal-title":"Science"},{"issue":"(1)","key":"2024021014360165900_jbmr3341-bib-0024","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nn.2467","article-title":"A robust and high-throughput Cre reporting and characterization system for the whole mouse brain","volume":"13","author":"Madisen","year":"2010","journal-title":"Nat Neurosci"},{"issue":"24","key":"2024021014360165900_jbmr3341-bib-0025","doi-asserted-by":"crossref","first-page":"10932","DOI":"10.1073\/pnas.0914642107","article-title":"A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses","volume":"107","author":"Matsumoto","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"(22)","key":"2024021014360165900_jbmr3341-bib-0026","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1242\/dev.02088","article-title":"Mice deficient in Ext2 lack heparan sulfate and develop exostoses","volume":"132","author":"Stickens","year":"2005","journal-title":"Development"},{"issue":"(3)","key":"2024021014360165900_jbmr3341-bib-0027","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bone.2004.09.025","article-title":"EXT1 regulates chondrocyte proliferation and differentiation during endochondral bone development","volume":"36","author":"Hilton","year":"2005","journal-title":"Bone"},{"issue":"(5)","key":"2024021014360165900_jbmr3341-bib-0028","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bone.2011.02.001","article-title":"Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones","volume":"48","author":"Zak","year":"2011","journal-title":"Bone"},{"issue":"(5)","key":"2024021014360165900_jbmr3341-bib-0029","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1073\/pnas.0910875107","article-title":"A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes","volume":"107","author":"Jones","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"(9)","key":"2024021014360165900_jbmr3341-bib-0030","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/jbmr.2820","article-title":"Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) fibrodysplasia ossificans progressiva (FOP) mutation","volume":"31","author":"Chakkalakal","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"(2)","key":"2024021014360165900_jbmr3341-bib-0031","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1006\/excr.1996.0103","article-title":"CD44 expression in fetal rat bone: in vivo and in vitro analysis","volume":"223","author":"Jamal","year":"1996","journal-title":"Exp Cell Res"},{"key":"2024021014360165900_jbmr3341-bib-0032","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2016.06.014","article-title":"Targeted stimulation of retinoic acid receptor-gamma mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model","volume":"90","author":"Pavey","year":"2016","journal-title":"Bone"},{"key":"2024021014360165900_jbmr3341-bib-0033","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bone.2016.02.008","article-title":"Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent","volume":"90","author":"Sinha","year":"2016","journal-title":"Bone"},{"key":"2024021014360165900_jbmr3341-bib-0034","first-page":"545","author":"Armstrong","year":"1994"},{"issue":"(44)","key":"2024021014360165900_jbmr3341-bib-0035","doi-asserted-by":"crossref","first-page":"18886","DOI":"10.1073\/pnas.1009244107","article-title":"Retinoic acid regulates bone morphogenic protein signal duration by promoting the degradation of phosphorylated Smad1","volume":"107","author":"Sheng","year":"2010","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/4\/658\/56653079\/jbmr3341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/4\/658\/56653079\/jbmr3341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:00:38Z","timestamp":1710342038000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/33\/4\/658-666\/7605673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,11,9]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3341","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,1]]},"published":{"date-parts":[[2017,11,9]]}}}